TY - JOUR
T1 - Molecular dynamics simulations and molecular flooding studies of the retinoid X-receptor ligand binding domain
AU - Gray, Geoffrey M.
AU - Ma, Ning
AU - Wagner, Carl
AU - van der Vaart, Arjan
N1 - Funding Information:
This work was supported by the National Institutes of Health (R15 CA139364-O1A2) and the Eward N. and Della L. Thome Memorial Foundation. Computer time was provided by USF Research Computing, sponsored in part by NSF MRI CHE-1531590.
Publisher Copyright:
© 2017, Springer-Verlag Berlin Heidelberg.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Bexarotene is an FDA approved retinoid X-receptor (RXR) agonist for the treatment of cutaneous T-cell lymphoma, and its use in other cancers and Alzheimer’s disease is being investigated. The drug causes serious side effects, which might be reduced by chemical modifications of the molecule. To rationalize known agonists and to help identify sites for potential substitutions we present molecular simulations in which the RXR ligand-binding domain was flooded with a large number of drug-like molecules, and molecular dynamics simulations of a series of bexarotene-like ligands bound to the RXR ligand-binding domain. Based on the flooding simulations, two regions of interest for ligand modifications were identified: a hydrophobic area near the bridgehead and another near the fused ring. In addition, positional fluctuations of the phenyl ring were generally smaller than fluctuations of the fused ring of the ligands. Together, these observations suggest that the fused ring might be a good target for the design of higher affinity bexarotene-like ligands, while the phenyl ring is already optimized. In addition, notable differences in ligand position and interactions between the RXRα and RXRβ were observed, as well as differences in hydrogen bonding and solvation, which might be exploited in the development of subspecies-specific ligands.
AB - Bexarotene is an FDA approved retinoid X-receptor (RXR) agonist for the treatment of cutaneous T-cell lymphoma, and its use in other cancers and Alzheimer’s disease is being investigated. The drug causes serious side effects, which might be reduced by chemical modifications of the molecule. To rationalize known agonists and to help identify sites for potential substitutions we present molecular simulations in which the RXR ligand-binding domain was flooded with a large number of drug-like molecules, and molecular dynamics simulations of a series of bexarotene-like ligands bound to the RXR ligand-binding domain. Based on the flooding simulations, two regions of interest for ligand modifications were identified: a hydrophobic area near the bridgehead and another near the fused ring. In addition, positional fluctuations of the phenyl ring were generally smaller than fluctuations of the fused ring of the ligands. Together, these observations suggest that the fused ring might be a good target for the design of higher affinity bexarotene-like ligands, while the phenyl ring is already optimized. In addition, notable differences in ligand position and interactions between the RXRα and RXRβ were observed, as well as differences in hydrogen bonding and solvation, which might be exploited in the development of subspecies-specific ligands.
KW - Drug design
KW - Molecular dynamics
KW - Retinoid X receptor
KW - Simulation
UR - http://www.scopus.com/inward/record.url?scp=85014690901&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014690901&partnerID=8YFLogxK
U2 - 10.1007/s00894-017-3260-9
DO - 10.1007/s00894-017-3260-9
M3 - Article
C2 - 28251414
AN - SCOPUS:85014690901
SN - 1610-2940
VL - 23
JO - Journal of Molecular Modeling
JF - Journal of Molecular Modeling
IS - 3
M1 - 98
ER -